GRALBTEM2401 - CME/CMLE - Newly FDA Approved Alzheimer’s Biomarkers Testing: How to Implement Such Tests in Core Laboratory?

Course Description

Newly FDA Approved Alzheimer’s Biomarkers Testing: How to Implement Such Tests in Core Laboratory?

Activity Description:

The diagnostic paradigm for Alzheimer's disease (AD) has rapidly shifted in the last five years as fluid-based biomarker testing has emerged as a reliable, accurate, and accessible means to detect amyloid pathology when evaluating a patient for cognitive decline. This activity is designed to help pathologists and laboratory professionals gain an understanding of plasma testing for markers such as Abeta40/42, P-tau181, and P-tau217 which are rapidly appearing in the commercial space and how healthcare providers have begun incorporating these tests into routine neurology practice. This course will help participants to understand the advantages and limitations of these assays as well as their potential application when a physician is evaluating a patient for AD.

Course topics include:

The role of plasma-based biomarker diagnostics in the clinical evaluation of patients with cognitive impairment who are being evaluated for AD

Scientific and clinical considerations for the pathologist when evaluating such plasma-based biomarker assays

Practical considerations for implementing these assays in the clinical laboratory

Faculty/Authors
Amitava Dasgupta, Ph.D.
Professor, Pathology and Laboratory Medicine
The University of Kansas Health System
University of Kansas, Kansas City, Kansas

Kelsey Woodard, MLS (ASCP)
Chemistry and Special Chemistry Supervisor, Clinical Laboratory
The University of Kansas Health System
University of Kansas, Kansas City, Kansas

Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning and Improvement

CME/CMLE Credit: 1.0
Estimated Completion Time: 1 hour
Format: Online educational activity

Target Audience

This activity has been designed to meet the educational needs of pathologists and laboratory professionals.  

Credit Designation Statement

The ASCP designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ASCP designates this activity for a maximum of 1.0 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, option 2, in the US & Canada or internationally at access code + 3-1-312-541-4890. Monday-Friday, 8am-5pm CT.

Method of Participation

To complete the activity and receive credit, the participant must participate in the course. CME certificates will be provided on-line. 

Commercial Support

This activity is supported by independent educational grants from Lily.

Instructions

To claim CME/CMLE credit for the exercise, do the following:

Review the Faculty Disclosure.
Click Go to Content and click the first module of the course.
Complete the Demographic Survey.
Complete the Pre-Test.
Review the Educational Activity.
Complete and submit the Post Exam. You will have a maximum of three attempts to obtain the required score. You will be notified if you have met the credit requirements after each attempt.
Submit the course Evaluation.
Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Faculty Disclosure

Release Dates: 10/21/2024
Review Date:
Expiration Date: 10/21/2027

Course Objectives

Upon completion of this activity, you will be able to:

Explain the basic pathophysiology of Alzheimer’s disease and most recently approved drugs for treatment.

Describe the clinical utility of AD biomarkers and correlation of biomarkers with findings of brain imaging.

Discuss commercially available immunoassays for measuring AD biomarkers and implementation in the core lab.

Summary


Availability:	On-Demand


Credit Offered:	1 CME/CMLE Credit